Skip to Content
Merck
CN
  • Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?

Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?

Urology (2013-06-29)
Michael A Liss, Kristen K Nakamura, Rachel Meuleners, Surendra B Kolla, Atreya Dash, Ellena M Peterson
ABSTRACT

To investigate the performance of screening rectal cultures obtained 2 weeks before transrectal prostate biopsy to detect fluoroquinolone-resistant organisms and again at transrectal prostate biopsy. After institutional review board approval for observational study, we obtained a rectal culture on patients identified for a prostate biopsy but before antibiotic prophylaxis from September 12, 2011 to April 23, 2012. The specimen was cultured onto MacConkey agar with and without 1 μg/mL ciprofloxacin. We then obtained a second rectal culture immediately before prostate biopsy after 24 hours of ciprofloxacin prophylaxis. All cultures were blinded to the practitioner until the end of the study. Of 108 patients enrolled, 58 patients had both rectal cultures for comparison. The median time duration between cultures was 14 (6-119) days. There were 54 of 58 concordant pairs (93%), which included 47 negative cultures and 7 positive cultures; 2 patients (3%) who were culture negative from the first screening culture became positive at biopsy. Sensitivity, specificity, negative, positive predictive values, and area under the operator curve were 95.9%, 77.8%, 95.9%, 77.8%, and 0.868, respectively. When Pseudomonas spp. are removed from the analysis, the area under the curve is increased to 0.927. Screening rectal cultures 2 weeks before prostate biopsy has favorable test performance, suggesting screening cultures give an accurate estimate of fluoroquinolone-resistant colonization.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ciprofloxacin HCl, Pharmaceutical Secondary Standard; Certified Reference Material
Ciprofloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Ciprofloxacin hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard